[
  {
    "ts": "2026-01-27T12:14:00+00:00",
    "headline": "Gene Therapy Investment Trends Strategic Intelligence Report 2026: Market to Reach $42.26 Billion by 2033 | Astute Analytica",
    "summary": "The global gene therapy market is experiencing rapid expansion, driven by advancements in CRISPR and viral vectors. The market focuses on treating genetic disorders, cancer, and rare diseases, with North America leading in adoption. Key players include Novartis, Gilead, and Sarepta.Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.2",
    "url": "https://finance.yahoo.com/news/gene-therapy-investment-trends-strategic-121400413.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "77de9d55-d31a-3958-9f77-8d5144f2648b",
      "content": {
        "id": "77de9d55-d31a-3958-9f77-8d5144f2648b",
        "contentType": "STORY",
        "title": "Gene Therapy Investment Trends Strategic Intelligence Report 2026: Market to Reach $42.26 Billion by 2033 | Astute Analytica",
        "description": "",
        "summary": "The global gene therapy market is experiencing rapid expansion, driven by advancements in CRISPR and viral vectors. The market focuses on treating genetic disorders, cancer, and rare diseases, with North America leading in adoption. Key players include Novartis, Gilead, and Sarepta.Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.2",
        "pubDate": "2026-01-27T12:14:00Z",
        "displayTime": "2026-01-27T12:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gene-therapy-investment-trends-strategic-121400413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gene-therapy-investment-trends-strategic-121400413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SRPT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T21:05:00+00:00",
    "headline": "Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026",
    "summary": "FOSTER CITY, Calif., January 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial results and provide a business update.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-release-fourth-quarter-210500609.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "6fd048d5-ed7a-3eaa-a8d5-eede4564bed0",
      "content": {
        "id": "6fd048d5-ed7a-3eaa-a8d5-eede4564bed0",
        "contentType": "STORY",
        "title": "Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026",
        "description": "",
        "summary": "FOSTER CITY, Calif., January 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial results and provide a business update.",
        "pubDate": "2026-01-27T21:05:00Z",
        "displayTime": "2026-01-27T21:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c15e39a3f49948a51cfacae0f6235b52",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GscEvyQOY4I_JotbI2uSRg--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c15e39a3f49948a51cfacae0f6235b52.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0qAPMD1qHTy7OuekZEIE7w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c15e39a3f49948a51cfacae0f6235b52.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-release-fourth-quarter-210500609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-release-fourth-quarter-210500609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]